Andere Sprachen NANO MRNA Co.,Ltd.

Aktien

A0NCX4

JP3651120002

4571

Markt geschlossen - Japan Exchange Andere Börsenplätze 08:00:00 07.06.2024			% 5 Tage	% 1. Jan.
172 ^JPY	+1,78 %		-1,15 %	-9,47 %

2023	NANO MRNA Co., Ltd. und die Kao Corporation vereinbaren eine umfassende Forschungskooperation zur Entdeckung von mRNA-Wirkstoffen	CI
2023	NanoCarrier Co., Ltd. meldet Ergebnis für das Geschäftsjahr bis zum 31. März 2023	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

NANO MRNA, Kao Tie Up to Develop mRNA Therapies for Allergic Diseases	15.11.
NANO MRNA Co., Ltd. and Kao Corporation Agree a Comprehensive Collaborative Research for mRNA Drug Discovery	14.11.
NanoCarrier Co., Ltd. announced that it has received ¥13.6793 million in funding from Axcelead Inc., IPGaia, Inc.	12.06.23
NanoCarrier Co., Ltd. announced that it expects to receive ¥13.6793 million in funding from Axcelead Inc., IPGaia, Inc.	26.05.23
NanoCarrier Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	12.05.23
US Patent Office Grants Patrys Two New Deoxymab Patents	18.04.23
NanoCarrier Co., Ltd. announced that it has received Â¥1.11096909 billion in funding from Whiz Partners Inc.	13.02.23
NanoCarrier Co., Ltd. announced that it expects to receive ¥1.11096909 billion in funding from Whiz Partners Inc.	25.01.23
NanoCarrier Co., Ltd. Reports Earnings Results for the Half Year Ended September 30, 2022	11.11.22
NanoCarrier : Commences in Domestic Patients Administration of VB-111, a gene therapy product Global Phase III Trial in Platinum-Resistant Ovarian Cancer	10.06.21
NanoCarrier Co., Ltd. Commences in Domestic Patients Administration of VB-111, A Gene Therapy Product Global Phase III Trial in Platinum-Resistant Ovarian Cancer	10.06.21
NanoCarrier Co., Ltd. announced that it expects to receive ¥1.15292206 billion in funding from THE KENKO FUTURE Limited Partnership	23.04.21
Nanocarrier : Concludes NC-6004 Phase III Clinical Study for Pancreatic Cancer	30.11.20
NanoCarrier Announces the Conclusion of NC-6004 Phase III Clinical Study for Pancreatic Cancer	27.11.20
Nanocarrier : Administers Head and Neck Cancer Drug NC-6004 to First Patient	06.11.20
Nanocarrier Co., Ltd. Starts Administering NC-6004 in the Phase IIb Clinical Study in Combination with Keytruda for Head and Neck Cancer	05.11.20
NanoCarrier Presents Favorable Data from Phase IIa Portion of NC-6004 Phase II Clinical Study in Combination with Keytruda	26.10.20
NanoCarrier Co., Ltd. completed the acquisition remaining 92.62% AccuRna, Inc. from Fast Track Initiative No. 2 Investment Business Limited Liability, SMBC Venture Capital Co., Ltd., Innovation Platform Development No. 1 Fund, fund managed by UTokyo Innovation Platform Co., Ltd. and Kazunori Kataoka.	30.09.20
NanoCarrier Co., Ltd. Announces the First Participant Dosed in Investigator-Initiated Phase I Clinical Trial in Patients with Breast Cancer in Japan	03.09.20
NanoCarrier Co., Ltd. signed an agreement to acquire remaining 92.62% AccuRna, Inc. from Fast Track Initiative No. 2 Investment Business Limited Liability, SMBC Venture Capital Co., Ltd., Innovation Platform Development No. 1 Fund, fund managed by UTokyo Innovation Platform Co., Ltd. and Kazunori Kataoka for ¥1.7 billion.	15.07.20

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen NANO MRNA Co.,Ltd.

Aktien

A0NCX4

JP3651120002

4571

Andere Sprachen

Filter